Better Together: Discovery Life Sciences and AllCells Join Forces
January 30, 2023In July of 2022, AllCells was acquired by Discovery Life Sciences (Discovery), the Biospecimen and Biomarker Specialists™. By combining over 30 years of cell and gene therapy (CGT) expertise, our […]
How AllCells’ Expanded Donor Collection Facilities Help You to Recruit the Right Donors and Scale Your Cell and Gene Therapy Development
November 7, 2022Unlike classical therapeutics (i.e., monoclonal antibodies), the raw starting materials for cell and gene therapies (CGTs) are derived from patient or donor cells. As such, these sources are not mass-produced […]
The Key to Developing Good Manufacturing Practice (GMP) Biomaterials for Cell and Gene Therapy Development
October 3, 2022A decade ago, the emergence of new immunotherapies in the cell and gene therapy (CGT) space opened up new avenues to treat disease, sparking excitement across the industry. However, the […]
Overcoming the Global Biomaterial Supply Chain Challenge for the Development of CAR-T Therapies
September 21, 2022By 2026, commercial chimeric antigen receptor (CAR)-T cell therapies are on track to make up the largest share of oncology drug sales for pediatric and young adult patients1. This is […]
Dual Mobilization Enhances CD34+ Yield Across All Donor Types
August 1, 2022Mobilized peripheral blood has now surpassed bone marrow as the preferred source of CD34+ hematopoietic stem and progenitor cells (HSPCs) for allogeneic hematologic transplantation and translational medicines because both the […]
The Therapeutic Potential of HSC-based Gene Therapies
July 25, 2022Hematopoietic stem cells (HSCs) have immense therapeutic potential because of their ability for both self-renewal and multi-lineage differentiation to maintain hematopoietic homeostasis. This rare population of cells are characterized by […]
A Decade of Innovation: CAR-T Successes and Latest Developments
July 6, 2022After a decade of innovation, chimeric antigen receptor (CAR)-T cell therapy remains at the forefront of the cell and gene therapy space, continuing to forge new ground to treat previously […]
Why You Should Start Clinical Grade Cell Supply Discussions Early in Cell and Gene Therapy Development
May 24, 2022Cell and gene therapies represent an expanding category of transformative medicines with the potential to change the way we treat human diseases. Broadly, these novel therapies include both in vivo […]
What You Need to Know About Regenerative Medicine in 2022: Industry and Tech Trends
April 20, 2022Growth in the Regenerative Medicine Field The regenerative medicine sector is on track for another watershed year where clinical progress, continued growth, and segmentation into new disease areas affecting larger […]
AllCells Opens a New Collection Facility in Houston, Texas
March 29, 2022Expanding Its Donor Network AllCells, the leading provider of human hematological products and services, is pleased to announce the opening of a new, 3600 sq ft LeukoLab cell collection facility […]
